Navigation Links
Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman
Date:11/23/2009

CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment of pharmaceutical industry veteran Errol B. De Souza as Ligon's Executive Chairman of the Board.

"I'm very pleased to welcome Errol De Souza as Executive Chairman of the Board," said Patrick Kleyn, Ligon's chief executive officer and co-founder. He added, "Errol's breadth of experience in the life sciences industry -- particularly his leadership taking drug candidates from exploratory research through clinical development -- will be an asset to Ligon as we advance our current drug discovery campaigns targeting cancer and coagulations disorders, utilizing our proprietary small molecule microarray platform."

Dr. De Souza commented, "I look forward to chairing Ligon's Board, and contributing to the forward momentum being built by the company in discovering small molecule drugs against disease targets that others have found intractable. Ligon's unique and proprietary small molecule microarray technology offers compelling advantages, including broad applicability to all target classes, unprecedented scale of parallel screening, and minimal protein requirements. I believe Ligon has what it takes to leverage this already validated technology."

Errol B. De Souza, Ph.D. is a seasoned pharma and biotech industry leader with 20 years of experience in senior level Research & Development (R&D) and management positions at Aventis, Hoechst Marion Roussel (HMR), DuPont Merck, Neurocrine Biosciences, Synaptic Pharmaceuticals and Archemix. His R&D experience spans from leading large R&D organizations at DuPont Merck (Director of CNS Diseases Research), HMR (Senior Vice President and Head of Global Lead Generation) with worldwide responsibilities for chemistry, chemical development, biotechnology, high throughput screening and core research functions to Aventis (Senior Vice President and Site Head of US Drug Innovation and Approval) where he had worldwide responsibilities for managing the CNS, Immunology and Inflammatory Diseases pipeline as well as administrative responsibilities for the entire R&D organization in the US including the Global Drug Development Center.

Dr. De Souza's particular focus has been on the developing innovative approaches to accelerate progression of compounds from the candidate to clinical proof-of-concept stage and beyond through development of biomarker and pharmacogenomic strategies and utilization of imaging techniques. His experience on the biotech side spans from starting companies (Founder, Chief Scientific Officer and Executive Vice President of R&D at Neurocrine), to leading companies (President & CEO of Synaptic Pharmaceuticals and Archemix, Inc) and experience on several Boards of Directors and Scientific Advisory Boards of both public and private companies. In these capacities, he has successfully raised capital in both private and public environments and been involved in multiple collaborations with large pharmaceutical companies.

About Ligon Discovery

Ligon Discovery is a Harvard spinout that leverages a patented platform technology to identify pre-clinical drug candidates. The company's high-throughput microarray "chip" transforms the speed of the drug discovery process and expands the scope of new drug prospecting to include previously intractable targets. With funding from incTANK Ventures, the team has deployed the SMM technology, originally invented at Harvard University and further developed at the Broad Institute (founded by MIT and Harvard University) in Cambridge, and has established one of the largest small molecule screening capabilities in the industry. Using this facility, Ligon has successfully completed screens in the fields of coagulation and cancer, and is actively pursuing drug discovery in other areas of high unmet medical need. For more information, visit www.ligondiscovery.com.

SOURCE Ligon Discovery, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
2. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
3. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
4. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
5. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
6. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
7. American Brain Tumor Association Calls for Discovery Research
8. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
9. International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):